{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang C"],"funding":["NIBIB NIH HHS","NIDA NIH HHS","NCRR NIH HHS"],"pagination":["7999-8009"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4191584"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["57(19)"],"pubmed_abstract":["Epigenetic enzymes are now targeted to treat the underlying gene expression dysregulation that contribute to disease pathogenesis. Histone deacetylases (HDACs) have shown broad potential in treatments against cancer and emerging data supports their targeting in the context of cardiovascular disease and central nervous system dysfunction. Development of a molecular agent for non-invasive imaging to elucidate the distribution and functional roles of HDACs in humans will accelerate medical research and drug discovery in this domain. Herein, we describe the synthesis and validation of an HDAC imaging agent, [(11)C]6. Our imaging results demonstrate that this probe has high specificity, good selectivity, and appropriate kinetics and distribution for imaging HDACs in the brain, heart, kidney, pancreas, and spleen. Our findings support the translational potential for [(11)C]6 for human epigenetic imaging."],"journal":["Journal of medicinal chemistry"],"pubmed_title":["In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs."],"pmcid":["PMC4191584"],"funding_grant_id":["S10 RR026666","S10 RR022976","P41 EB015896","R01 DA028301","R01DA028301","S10RR029495","R01DA030321","K99 DA037928","S10 RR019933","S10RR017208","S10RR019933","S10 RR029495","S10RR022976","S10 RR017208","P41EB015896","R01 DA030321","S10 RR023385","S10RR026666"],"pubmed_authors":["Kim SW","Schroeder FA","Wang C","Borra R","Wey HY","Wagner FF","Hooker JM","Reis S","Holson EB","Haggarty SJ"],"additional_accession":[]},"is_claimable":false,"name":"In vivo imaging of histone deacetylases (HDACs) in the central nervous system and major peripheral organs.","description":"Epigenetic enzymes are now targeted to treat the underlying gene expression dysregulation that contribute to disease pathogenesis. Histone deacetylases (HDACs) have shown broad potential in treatments against cancer and emerging data supports their targeting in the context of cardiovascular disease and central nervous system dysfunction. Development of a molecular agent for non-invasive imaging to elucidate the distribution and functional roles of HDACs in humans will accelerate medical research and drug discovery in this domain. Herein, we describe the synthesis and validation of an HDAC imaging agent, [(11)C]6. Our imaging results demonstrate that this probe has high specificity, good selectivity, and appropriate kinetics and distribution for imaging HDACs in the brain, heart, kidney, pancreas, and spleen. Our findings support the translational potential for [(11)C]6 for human epigenetic imaging.","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Oct","modification":"2021-02-25T08:23:50Z","creation":"2019-03-27T01:37:19Z"},"accession":"S-EPMC4191584","cross_references":{"pubmed":["25203558"],"doi":["10.1021/jm500872p"]}}